ZA201501795B - Method of synthesizing thyroid hormone analogs and polymorphs thereof - Google Patents
Method of synthesizing thyroid hormone analogs and polymorphs thereofInfo
- Publication number
- ZA201501795B ZA201501795B ZA2015/01795A ZA201501795A ZA201501795B ZA 201501795 B ZA201501795 B ZA 201501795B ZA 2015/01795 A ZA2015/01795 A ZA 2015/01795A ZA 201501795 A ZA201501795 A ZA 201501795A ZA 201501795 B ZA201501795 B ZA 201501795B
- Authority
- ZA
- South Africa
- Prior art keywords
- polymorphs
- thyroid hormone
- hormone analogs
- synthesizing
- synthesizing thyroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201501795B true ZA201501795B (en) | 2021-10-27 |
Family
ID=50278769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/01795A ZA201501795B (en) | 2012-09-17 | 2015-03-16 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Country Status (32)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2795450T3 (es) * | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) * | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CN109574995B (zh) * | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
| TW202615431A (zh) * | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CN119552152A (zh) * | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN112442013B (zh) * | 2019-09-04 | 2022-07-26 | 广东东阳光药业有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CA3158379A1 (en) * | 2019-11-26 | 2021-06-03 | Hejun Lv | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| WO2021121210A1 (zh) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2022041026A1 (en) * | 2020-08-27 | 2022-03-03 | InventisBio Co., Ltd. | Pyridazinone compounds |
| KR20230066408A (ko) * | 2020-09-10 | 2023-05-15 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도 |
| US12616701B2 (en) | 2020-10-19 | 2026-05-05 | Assia Chemical Industries Ltd | Solid state forms of Resmetirom |
| CN114437042A (zh) * | 2020-11-03 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 酞嗪类化合物的晶型及其制备方法 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| WO2022165227A1 (en) | 2021-02-01 | 2022-08-04 | Madrigal Pharmaceuticals, Inc. | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| TW202337470A (zh) | 2021-09-27 | 2023-10-01 | 美商瑪德瑞高製藥公司 | 用於縮減肝臟體積之瑞美替隆 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN116768802B (zh) * | 2023-05-25 | 2025-11-21 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗的合成方法 |
| JP2026521649A (ja) | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| CN117263870B (zh) * | 2023-09-21 | 2026-02-06 | 江西同和药业股份有限公司 | 一种Resmetirom关键中间体III的制备方法 |
| EP4762048A2 (en) | 2023-10-16 | 2026-06-24 | Cipla Limited | Resmetirom polymorphs and process for their preparation |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| AU2024408289A1 (en) | 2023-12-22 | 2026-08-06 | Tangram Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025164161A1 (ja) * | 2024-01-29 | 2025-08-07 | シオノギファーマ株式会社 | カンナビジオールの溶媒和物及びカンナビジオールの精製方法 |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025191457A1 (en) * | 2024-03-13 | 2025-09-18 | Morepen Laboratories Limited | Process for the preparation of pyridazinone derivative |
| CN119019375A (zh) * | 2024-08-14 | 2024-11-26 | 奥锐特药业(天津)有限公司 | 一种瑞司美替罗新晶型及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| CN119306670A (zh) * | 2024-10-12 | 2025-01-14 | 北京海美桐医药科技有限公司 | 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法 |
| WO2026107045A1 (en) | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| RU2346950C2 (ru) | 2003-01-28 | 2009-02-20 | Академис Зикенхейс Лейден | Пептидные ингибиторы токсинов, производные ll-37 |
| WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| US20050287667A1 (en) | 2004-06-01 | 2005-12-29 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| BRPI0517947A (pt) | 2004-11-02 | 2008-10-21 | Univ Northwestern | composto de piridazina, composições e métodos |
| JPWO2007000913A1 (ja) | 2005-06-27 | 2009-01-22 | 国立大学法人東京工業大学 | 高級脂肪酸エステルの製造方法 |
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| ES2351274T3 (es) * | 2007-06-06 | 2011-02-02 | Torrent Pharmaceuticals Ltd | Nuevos compuestos. |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| WO2015123256A1 (en) | 2014-02-14 | 2015-08-20 | Cempra Pharmaceuticals, Inc. | Compositions and methods for treating diabetes and liver diseases |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| TW202615431A (zh) | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CN119552152A (zh) | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2013
- 2013-09-17 ES ES13837402T patent/ES2795450T3/es active Active
- 2013-09-17 IL IL314360A patent/IL314360B2/en unknown
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/da active
- 2013-09-17 SI SI201332113T patent/SI4406594T1/sl unknown
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en not_active Ceased
- 2013-09-17 PL PL24173563.8T patent/PL4406594T3/pl unknown
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/ko active Active
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/ja active Active
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/pt active IP Right Grant
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/ru unknown
- 2013-09-17 FI FIEP24173563.8T patent/FI4406594T3/fi active
- 2013-09-17 DK DK24173563.8T patent/DK4406594T3/da active
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 TW TW108132827A patent/TWI755628B/zh active
- 2013-09-17 LT LTEP24173563.8T patent/LT4406594T/lt unknown
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/zh active Pending
- 2013-09-17 IL IL288133A patent/IL288133B2/en unknown
- 2013-09-17 TW TW110117935A patent/TWI804870B/zh active
- 2013-09-17 TW TW107137798A patent/TWI681957B/zh active
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 EP EP24173563.8A patent/EP4406594B1/en active Active
- 2013-09-17 IL IL320269A patent/IL320269A/en unknown
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/ko active Active
- 2013-09-17 PT PT241735638T patent/PT4406594T/pt unknown
- 2013-09-17 MX MX2015003418A patent/MX364661B/es active IP Right Grant
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/ko active Active
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/ko not_active Ceased
- 2013-09-17 ES ES20157696T patent/ES2907926T3/es active Active
- 2013-09-17 EP EP25200792.7A patent/EP4691557A3/en active Pending
- 2013-09-17 HR HRP20251398TT patent/HRP20251398T1/hr unknown
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/da active
- 2013-09-17 MX MX2018014924A patent/MX395148B/es unknown
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/zh active Active
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/pt not_active Application Discontinuation
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/ru active
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 ES ES24173563T patent/ES3053122T3/es active Active
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 SM SM20250439T patent/SMT202500439T1/it unknown
- 2013-09-17 TW TW102133687A patent/TWI652260B/zh active
- 2013-09-17 AR ARP130103332A patent/AR092872A1/es active IP Right Grant
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 RS RS20251117A patent/RS67728B1/sr unknown
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
-
2016
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/ja active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/ja active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/ja active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/ja active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/ja active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en not_active Abandoned
-
2023
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en not_active Abandoned
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/ja active Pending
-
2025
- 2025-09-03 JP JP2025145966A patent/JP2025179154A/ja active Pending
-
2026
- 2026-02-20 LT LTPA2026507C patent/LTPA2026507I1/lt unknown
- 2026-02-26 FR FR26C1009C patent/FR26C1009I1/fr active Active
- 2026-03-02 NL NL301369C patent/NL301369I2/nl unknown
- 2026-03-03 FI FIC20265007C patent/FIC20265007I1/fi unknown
- 2026-03-03 NO NO2026010C patent/NO2026010I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275393A (en) | A method of synthesizing thyroid hormone analogues and their polymorphs | |
| AP3965A (en) | Anthelminitic compounds and compositions and method of using thereof | |
| EP2826205A4 (en) | METHOD OF NAVIGATING THROUGH DIGITAL CONTENTS | |
| EP2800476A4 (en) | FEEDING METHOD | |
| EP2914293A4 (en) | METHOD OF USE OF FVIII POLYPEPTIDE | |
| GB201207208D0 (en) | Compound and method of manufacture | |
| EP2800747A4 (en) | POLYMORPHY OF PERAMPANEL | |
| IL235115A (en) | Method for Preparing Imidodisulfuryl Compounds | |
| SG11201405606RA (en) | Method for preparation of medetomidine | |
| GB201220155D0 (en) | Method of manufacture | |
| IL238515A0 (en) | A method for the preparation of alpha-galactosyl ceramide compounds | |
| GB201215942D0 (en) | Method of treatent | |
| ZA201503833B (en) | Method of hemoglobin-f determination | |
| IL241475A0 (en) | method for synthesis | |
| EP2928469A4 (en) | POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS | |
| IL233446A0 (en) | Polymorphic forms of paramphenel | |
| GB201211168D0 (en) | Method of feeding | |
| GB201211170D0 (en) | Method of feeding | |
| GB201211169D0 (en) | Method of feeding | |
| GB201211167D0 (en) | method of feeding | |
| GB201211166D0 (en) | Method of feeding | |
| GB201203868D0 (en) | Method of feeding | |
| GB201200132D0 (en) | Method of feeding | |
| SG10201610527UA (en) | Mixotrophic method of aquaculture | |
| TWM432415U (en) | Improved structure of walk aid apparatus |